MaxCyte (NASDAQ:MXCT; LSE:MXCT) has appointed Ali Soleymannezhad as chief commercial officer, effective September 11, 2024.
Prior to this role, Mr. Soleymannezhad served as executive vice president of bioprocessing at MaxCyte. He brings 20 years of technical sales, marketing, and product development to his new position, where he will lead the MaxCyte’s commercial operations to increase adoption of the ExPERT platform, provide best-in-class scientific, technical, and regulatory support to customers, and expand the company’s market impact in cell and gene therapy.
“I am delighted to promote Ali to the role of Chief Commercial Officer,” said Maher Masoud, president and CEO of MaxCyte. “His diverse experience, skills, and leadership at MaxCyte as Executive Vice President of Bioprocessing have strengthened our organization’s product development and commercial strategies. We look forward to working alongside Ali as he leads our commercial efforts to drive future growth at MaxCyte.”